ClinicalTrials.gg
RecruitingNCT06157268READYCOMUpdated Aug 19, 2024

The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.

An observational study in Central Core Disease, Multi-Minicore Disease and Nemaline Myopathy, sponsored by Radboud University Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Radboud University Medical Center · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
2 Years and older
Sex
All
01

Study summary

Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies. Not much is known about the natural history and no curative treatment is available for these groups. Also patients report fatigability as one of their symptoms. The goal of this observational study is to study the natural history during 24 months to achieve trial readiness and to study the muscle fatigability in CCD/MmD, NEM and CNM.

Read the detailed description

Rationale: Patients with CCD/MmD, NEM and CNM report symptoms of weakness in the arms and legs. Other symptoms include weakness of the respiratory, facial and swallowing muscles. No treatments are available for congenital myopathies (CM) to slow down or cure the disease. A few type I-II trials have taken place and more are expected. Therefore it is important to reach trial readiness. To create trial readiness, there is a need for natural history study to create a detailed report of the disease course and a selection of the most sensitive clinical and functional outcome measures and biomarkers. Besides muscle weakness, several patients report muscle fatigability. This has not been investigated systematically in CM. The lack of evidence calls for a cross-sectional study assessing muscle fatigability and neuromuscular transmission in CM.

Objectives: i) To assess the natural disease course of CCD/MmD, NEM and CNM during 24 months. ii) To select relevant and sensitive clinical and functional outcome measures and biomarkers. iii) To assess the severity of muscle fatigability in CCD/MmD, NEM and CNM.

Study design: Patients with a genetically confirmed CCD/MmD, NEM or CNM will be able to participate in this study. The study consist of 2 parts. Part 1: a prospective cohort study with 5 visits every 6 months, for a total of 2 years. 45 patients will be included for this part. Part 2: an observational study with 2 visits. For this part 75 patients will be included. There will be an overlap in patients for the two parts. So a total of approximately 100 patients will be included. A large set of tests will be performed to assess the full capabilities of the patient, e.g. muscle strength/endurance, muscle imaging (MRI/ultrasound), activities, walking ability, quality of life, muscle fatigability and the feeling of fatigue.

02

Conditions studied

  • Central Core Disease
  • Multi-Minicore Disease
  • Nemaline Myopathy
  • Centronuclear Myopathy

Keywords

  • Natural history study
  • Outcome measures
  • Congenital myopathy
  • Muscle disease
03

In context

Myopathies, Structural, Congenital

24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.

This study's planned enrollment of 100 is above the median of 49 across 12 observational studies indexed under Myopathies, Structural, Congenital.

Browse Myopathies, Structural, Congenital studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

45 patients will be included in the natural history study and 75 patients in the fatigability study, with some patients in both studies. The participants will be equally divided over three groups (CCD/MmD, NEM, CNM). Patients will be identified through patient databases of the Radboudumc and UMC Utrecht and patient groups. If more than 15/25 patients per group are willing to participate, we will select patients based on age and severity to have a good representation of the entire/complete disease spectrum.

Eligibility criteria

Inclusion Criteria for the natural history:

  • 2 years or older
  • Willing and able to complete the measurement protocol
  • Willing and able to travel to Nijmegen and Utrecht
  • Dutch-speaking
  • Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)

Inclusion Criteria for the fatigability study:

  • 8-60 years old
  • Willing and able to complete the measurement protocol
  • Willing and able to travel to Nijmegen and Utrecht
  • Dutch-speaking
  • Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
  • Willing to stop taking pyridostigmine and/or salbutamol 24 hours before the visit.

Exclusion Criteria for both parts:

Other neuromuscular, psychiatric or neurological disorders.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Core myopathies

    Patients with a genetically confirmed core myopathy

    Other: Natural history and non therapeutical therapy

  • Nemaline myopathy

    Patients with a genetically confirmed nemaline myopathy

    Other: Natural history and non therapeutical therapy

  • Centronuclear myopathy

    Patients with a genetically confirmed centronuclear myopathy

    Other: Natural history and non therapeutical therapy

Interventions

  • OtherNatural history and non therapeutical therapy

    This study concerns a natural history study part and a muscle fatigability part. For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.

06

What researchers measure

Primary outcomes

  1. Change of Motor Function Measure (MFM)

    Global motor functioning. The main outcome is the change in MFM score over a period of 2 years. The scores of the patients will also be compared to reference values.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  2. Endurance shuttle test - fatigability part

    Patients walk/move blocks/move pegs at a personalised set speed. The main outcome is if the patient drops out due to the speed being too low. If the patient drops out the time until dropout is noted.

    Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.

Secondary outcomes

  1. Change of 6-minute walk test (6MWT) (5 years and older)

    How far the patient can walk in 6 minutes. The first and last minute will be compared to each other.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  2. Accelerometry - change of extent and intensity of physical activity in daily life (all ages)

    Physical activity in daily life will be assessed by wearing an wrist worn accelerometer (GENEActiv original devices) for 7 days.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  3. Change of bone density (DEXA scan) (6 years and older)

    The bone density of the spine and hip will be measured by a DEXA scan.

    Time frame: Change from baseline at 24 months

  4. Change of graded and timed rise from floor (5 years and older)

    The time it takes to rise from the floor

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  5. Handheld dynamometry (5 years and older)

    Maximal voluntary isometric contraction will be measured by handheld dynamometry (m. biceps brachii, m. quadriceps, grip strength, all bilaterally)

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  6. Creatine Kinase

    Blood level of Creatine Kinase

    Time frame: At baseline

  7. Vitamin D3

    Blood level of Vitamin D3

    Time frame: At baseline

  8. Calcium

    Blood level of calcium

    Time frame: At baseline

  9. Liver function panel

    Blood level of bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyltransferase GGT, albumin, bile acids and full blood count.

    Time frame: At baseline

  10. Manual muscle testing (MMT) (5 years and older)

    Muscle power of individual muscle groups can be assessed by muscle power measurements and graded in correspondence with the Medical Research Council (MRC) scale.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  11. Change in muscle fattening by quantitative lower extremity muscle MRI (10 years and older)

    A lower extremity muscle MRI will be performed in participants who are able to lie supine and still for 20 minutes and who are not dependent on respiratory equipment. Muscle fattening will be assessed by Regions of Interest (ROIs) (quantitative) and modified Mercuri score (semi-quantitative).

    Time frame: Change from baseline at 24 months

  12. Change of muscle atrophy by quantitative lower extremity muscle MRI (10 years and older)

    A lower extremity muscle MRI will be performed in participants who are able to lie supine and still for 20 minutes and who are not dependent on respiratory equipment. Atrophy will be assessed by muscle volume score (semi-quantitative).

    Time frame: Change from baseline at 24 months

  13. Change in muscle atrophy (cm) assessed by muscle ultrasound (all ages)

    Muscle atrophy of the leg, arm, back, abdominal muscles and diaphragm will be assessed by muscle ultrasound.

    Time frame: Change from baseline at 24 months

  14. Change in muscle fattening (echo-intensity) assessed by muscle ultrasound (all ages)

    Muscle fattening of the leg, arm, back, abdominal muscles and diaphragm will be assessed by muscle ultrasound.

    Time frame: Change from baseline at 24 months

  15. Range of motion (all ages)

    The range of motion of the elbows, fingers, knees and ankles is noted bilaterally by goniometry.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  16. Pulmonary function - change of forced vital capacity (percentage predicted) (5 years and older)

    Obtained with handheld spirometry in sit and supine.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  17. Pulmonary function - change of forced expiratory volume in the first second (5 years and older)

    Obtained with handheld spirometry in sit and supine.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  18. Pulmonary function - change of maximal expiratory pressure (cmH2O) (5 years and older)

    Obtained with handheld device.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  19. Pulmonary function - change of maximal inspiratory pressure (cmH2O) (5 years and older)

    Obtained with handheld device.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  20. Pulmonary function - change of sniff nasal inspiratory pressure (5 years and older)

    Obtained with handheld device.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  21. Vignos and Brooke scale (all ages)

    The Brooke (score 1-6) and Vignos (score 1-10) scales provide ordinal data to assess the upper and lower extremity functions. A lower score indicates more functionality.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  22. Isokinetic dynamometry (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part

    Peak torque, time to peak torque, change in torque from first third to last third, acceleration time and deceleration time for 3, 5 and 30 repetitions at a set speed. For the 30 repetitions how many repetitions until failure is also noted.

    Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.

  23. Change in surface electromyography (EMG) amplitude and median frequency during isokinetic dynamometry with surface EMG (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part

    On the quadriceps/hamstrings or biceps/triceps surface EMG amplitude and median frequency will be measured.

    Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.

  24. Repetitive nerve stimulation (RNS) (8-60 years old) - fatigability part

    We will stimulate the n. ulnaris, n. accesorius and n. facialis at 3 Hz to measure the m abductor digiti minimi, m. trapezius and m nasalis. The decrement/increment will be determined by the compound muscle action potential amplitude and area. The RNS will be performed before and after 60 seconds of voluntary contraction.

    Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.

  25. Checklist individual strength (CIS) questionnaire fatigue subscale (18 years and older)

    The CIS is a questionnaire rating four subscales: subjective tiredness, concentration, motivation and physical activity. It consists of 20 items on a 7-point scale. We will use the Fatigue subscale. A CIS fatigue scale ≥ 35 points to severe fatigue.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  26. Fatigue severity scale questionnaire (12 years and older)

    Nine-questions scale about the impact of fatigue on the patient's life. Each item is scored on a 7 point scale. A higher score indicates greater fatigue/greater impact of fatigue on daily life.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  27. PedsQL multidimensional fatigue scale (MFS) (2-17 years old)

    The PedsQL MFS assesses subjective fatigue in three domains with 6 items each, namely General Fatigue Scale, Sleep/Rest Fatigue Scale, and Cognitive Fatigue Scale. Each item is scored on a three point scale ranging from not at all to a lot for children aged 5-7 and a five point scale from never to almost always for the others. Higher scores indicates less symptoms.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  28. PROMIS Fatigue Short Form questionnaire (all ages)

    Consists of 8 items representing the most informative items from the PROMIS item bank. The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. For patients younger than 18 a parent proxy is also available. The items are scored form 1-5 with a higher score indicating more fatigue.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  29. McGill pain questionnaire (MPQ) (12 years and older)

    The MPQ consists of 4 components: a pain word list to state the type and intensity of the pain, questions about the effect on daily life, a visual-analogue scale for pain intensity and questions about the location and course of the pain.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  30. Wong-Baker Faces Pain Scale (2-11 years old)

    The Wong-Baker Faces Pain Scale was originally created for children to help them communicate about their pain. It has six types of faces ranging from no hurt (0) tot hurts worst (10).

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  31. PedsQL generic quality of life (2-17 years old)

    The PedsQL generic quality of life questionnaire consists of 8 items on physical functioning, 5 items on emotional functioning, 5 items on social functioning, and 5 items on school functioning. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  32. Short Form 36 (SF36) quality of life scale (18 years and older)

    The adult Quality of Life is measured by the SF36/RAND36 questionnaire. The SF36/RAND36 addresses eight concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. It has a total of 36 items.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  33. Activlim questionnaire (7-17 years old)

    ACTIVLIM assesses the ability to perform 22 activities of daily life on a 3-point scale from impossible to easy. The questionnaires will be answered by the parents of the patient.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  34. Impact on participation and autonomy (18 years and older)

    Questionnaire about participation and autonomy in daily life with 41 questions on a ordinal 3- or 5-point likert scale. Higher scores indicate more obstacles in participation and autonomy.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  35. Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-P) (18 years and older)

    USER-P Restrictions scale is a patients-reported outcome measures with 32 questions focusing on daily activities including school and work. Each item is scored on a 4-, 5-, and 6-point Likert scale. A higher score indicates more participation.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  36. Borg rating scale of perceived exertion (5 years and older)

    Borg Rating Scale of Perceived Exertion is a way of measuring physical activity intensity level. Perceived exertion is based on the physical sensations a person experiences during physical activity. It is scored 6-20 with a higher score indicating a greater perceived exertion. Participants will be asked to score the intensity level at the beginning and at the end of the 6MWT.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  37. Hospital anxiety and depression scale (18 years and older)

    Questionnaire about the main complaints of anxiety and depression with 7 items each on a 4-point Likert scale. A higher score indicates more complaints.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  38. PedsQL neuromuscular module (NMM) (2-17 years old)

    The PedsQL NMM questionnaire consists of 25 questions in three domains: Neuromuscular disease, communication and family resources. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  39. Resilience evaluation scale (18 years and older)

    9-Item questionnaire on psychological resilience with each item being scored from 0-4, higher scores indicating greater resilience.

    Time frame: Change from baseline at 6, 12, 18 and 24 months

  40. Effects of pyridostigmine and/or salbutamol (8-60 years old) - fatigability part

    We will ask patients if they use pyridostigmine and/or salbutamol. If they use it we will ask how often, what the effects are and how long those effects last.

    Time frame: At baseline of the fatigability part of the study

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Research data is open access shared upon publication, provided that this complies with privacy regulations. The Donders Repository is the default repository for sharing the investigators' data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Dec 5, 2023
StartActual
Mar 28, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06157268
Collaborators
UMC Utrecht
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Mar 28, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 19, 2024

Study contacts

Nicol Voermans, MD PhD
Contact
Nicol.Voermans@radboudumc.nl
+31650155770
Nicol Voermans, MD PhD
principal investigator · Radboud University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion